Financial Results, Dividends, Positive Study Results, and Upcoming Earnings Releases - Research Reports on Varian Medical, Regulus, Cummins, AEP and NextEra

NEW YORK, October 28, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Varian Medical Systems, Inc. (NYSE: VAR), Regulus Therapeutics Inc. (NASDAQ: RGLS), Cummins Inc. (NYSE: CMI), American Electric Power Co., Inc. (NYSE: AEP) and NextEra Energy, Inc. (NASDAQ: NEE). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7487-100free.

--
Varian Medical Systems, Inc. Research Reports
On October 22, 2014, Varian Medical Systems, Inc. (Varian Medical) announced its Q4 FY 2014 (period ended September 26, 2014) financial results with revenues at $812.1 million, up 5% YoY. The backlog at the end of FY 2014 was $3.2 billion, up 10% YoY. Net earnings were reported at $105.9 million or $1.02 per diluted share compared to $117.3 million or $1.08 per diluted share in Q4 FY 2013. Dow R. Wilson, President and CEO of Varian Medical Systems said, "The company's major businesses generated strong quarter-over-quarter order growth following a year of investment in expanding global infrastructure and R&D. Revenues grew as expected in our Oncology Systems business while soft X-ray tube sales led to slower growth in our Imaging Components business." Commenting on outlook, he added, "For the first quarter of fiscal year 2015, we expect combined revenues from our Oncology Systems and Imaging Components businesses as well as proton orders currently in backlog to grow by 0 to 2 percent. Earnings per diluted share for the total company, including the expected $0.09 per diluted share restructuring charge, should be in the range of $0.76 to $0.80." The full research reports on Varian Medical are available to download free of charge at:

http://www.analystsreview.com/Oct-28-2014/VAR/report.pdf

--
Regulus Therapeutics Inc. Research Reports
On October 22, 2014, Regulus Therapeutics Inc. (Regulus) announced that the Company has demonstrated human proof-of-concept with microRNA therapeutic from an ongoing clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122 ("miR-122"), for the treatment of hepatitis C virus infection ("HCV"). The interim results from the ongoing clinical study show that the treatment with a single subcutaneous dose of 2 mg/kg of RG-101 as monotherapy led to significant and sustained reductions in HCV RNA in a varied group of patients, including difficult to treat genotypes and patients who experienced viral relapse after a prior IFN-containing regimen. Kleanthis G. Xanthopoulos, Ph.D., President and CEO of Regulus said, "We believe these interim data are exceptional and provide strong evidence to support the rapid advancement of RG-101 into future clinical studies, while presenting a clear opportunity for a potentially disruptive therapy to the current HCV treatment paradigm." The full research reports on Regulus are available to download free of charge at:

http://www.analystsreview.com/Oct-28-2014/RGLS/report.pdf

--
Cummins Inc. Research Reports
On October 14, 2014, Cummins Inc. (Cummins) announced that its Board of Directors declared a quarterly cash dividend of $0.78 per share on its common stock, payable on December 1, 2014 to shareholders of record on November 20, 2014. The full research reports on Cummins are available to download free of charge at:

http://www.analystsreview.com/Oct-28-2014/CMI/report.pdf

--
American Electric Power Co., Inc. Research Reports
On October 23, 2014, American Electric Power Co., Inc. (AEP) announced its Q3 2014 financial results with revenue at $4.3 billion versus $4.2 billion in Q3 2013. AEP's operating earnings for the quarter stood at $493 million or $1.01 per share compared to $533 million or $1.10 per share in Q3 2013. The Company reported GAAP earnings of $493 million or $1.01 per share versus $433 million or $0.89 per share in Q3 2013. "Our solid operational and financial performance in the third quarter reflects the ongoing, steady success of our regulated earnings growth strategy. Our third-quarter 2014 operating results are down compared with 2013, due to the mild summer and our plan to accelerate spending and shift costs from future years into 2014," said Nicholas K. Akins, AEP Chairman, President and CEO. AEP informed that its management narrowed its 2014 operating earnings guidance range to $3.40 to $3.50 per share from $3.35 to $3.55 per share. The full research reports on AEP are available to download free of charge at:

http://www.analystsreview.com/Oct-28-2014/AEP/report.pdf

--
NextEra Energy, Inc. Research Reports
On October 16, 2014, NextEra Energy, Inc. (NextEra) announced that the Company intends to report its Q3 2014 financial results on Friday, October 31, 2014, before the opening of the New York Stock Exchange through a news release to be available on the investors section of its website. NextEra informed that it has also scheduled an investor presentation to discuss the results on the same day at 9:00 a.m. ET. As per Nextra, its Chairman and CEO Jim Robo, Vice Chairman and CFO Moray Dewhurst, and other members of the Company's senior management team will participate in the event. A listen-only webcast of the event and replay of the same will be available on the investors section of NextEra's website. The full research reports on NextEra are available to download free of charge at:

http://www.analystsreview.com/Oct-28-2014/NEE/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED